Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Toshihiko Kaneda
Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)
Cancer
Cancer Research
Oncology
Does Afatinib Plus Bevacizumab Combination Therapy Induce Positive Conversion of T790M in Previously-Negative Patients?
Oncotarget
Oncology
Related publications
Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations
OncoTargets and Therapy
Oncology
Pharmacology
Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Cancer Research
Cancer Research
Oncology
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
Oncologist
Cancer Research
Medicine
Oncology
Molecular Imaging for Detection of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Clinical and Translational Imaging
Nuclear Medicine
Radiology
Imaging
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer
Cancer Research
Cancer Research
Oncology
Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Influence of EGFR-activating Mutations on Sensitivity to Tyrosine Kinase Inhibitors in a KRAS Mutant Non-Small Cell Lung Cancer Cell Line
PLoS ONE
Multidisciplinary
A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition
OncoTargets and Therapy
Oncology
Pharmacology
JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary